Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.64 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.64 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.64 |
| ▸ | HPGD | P15428 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.37 |
| ▸ | MAPT | P10636 | 4/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL860540 | 1.00 | EHMT2 (0.64) | EHMT2EHMT1APOBEC3GHPGDKMT2A | |
| Phosphoric Acid SCHEMBL17592569 | 0.89 | EHMT2 (0.52) | EHMT2EHMT1APOBEC3GHPGDKMT2A | |
| SCHEMBL1271372 | 0.88 | EHMT2 (0.59) | EHMT2EHMT1APOBEC3GHPGDKMT2A | |
| Hydrochloric Acid SCHEMBL3978581 | 0.86 | EHMT2 (0.57) | EHMT2EHMT1APOBEC3GHPGDKMT2A | |
| SCHEMBL24599713 | 0.84 | EHMT2 (0.59) | EHMT2EHMT1APOBEC3GHPGDKMT2A | |
| SCHEMBL803314 | 0.84 | EHMT2 (0.59) | EHMT2EHMT1APOBEC3GHPGDKMT2A | |
| SCHEMBL15301017 | 0.84 | EHMT2 (0.59) | EHMT2EHMT1APOBEC3GHPGDKMT2A | |
| SCHEMBL16486465 | 0.84 | EHMT2 (0.59) | EHMT2EHMT1APOBEC3GHPGDKMT2A | |
| SCHEMBL16132722 | 0.84 | EHMT2 (0.59) | EHMT2EHMT1APOBEC3GHPGDKMT2A | |
| SCHEMBL26969574 | 0.84 | EHMT2 (0.59) | EHMT2EHMT1APOBEC3GHPGDKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250361260-A1 | NUCLEOTIDE ANALOGUES | SINGULAR GENOMICS SYSTEMS INC (US) | 2025-11-27 | — | — | US | disclosed |
| US-12215122-B2 | Nucleotide analogues | Singular Genomics Systems, Inc. (US) | 2025-02-04 | — | — | US | disclosed |
| US-20240400602-A1 | NUCLEOTIDE ANALOGUES | FIRST-CITIZENS BANK & TRUST COMPANY | 2024-12-05 | — | — | US | disclosed |
| US-12145960-B2 | Nucleotide analogues | Singular Genomics Systems, Inc. (US) | 2024-11-19 | — | — | US | disclosed |
| US-20240316036-A1 | DISULFIDE CONTAINING THERAPEUTICS AND DIAGNOSTICS | FIRST-CITIZENS BANK & TRUST COMPANY | 2024-09-26 | — | — | US | disclosed |
| US-20240269156-A1 | DISULFIDE CONTAINING THERAPEUTICS | FIRST-CITIZENS BANK & TRUST COMPANY | 2024-08-15 | — | — | US | disclosed |
| US-20240174709-A1 | NUCLEOTIDE ANALOGUES | FIRST-CITIZENS BANK & TRUST COMPANY | 2024-05-30 | — | — | US | disclosed |
| US-11958877-B2 | Nucleotide analogues | Singular Genomics Systems, Inc. (US) | 2024-04-16 | — | — | US | disclosed |
| US-11878993-B2 | Nucleotide analogues | Singular Genomics Systems, Inc. (US) | 2024-01-23 | — | — | US | disclosed |
| US-20230257414-A1 | NUCLEOTIDE ANALOGUES | FIRST-CITIZENS BANK & TRUST COMPANY | 2023-08-17 | — | — | US | disclosed |
| US-20230203083-A1 | NUCLEOTIDE ANALOGUES | FIRST-CITIZENS BANK & TRUST COMPANY | 2023-06-29 | — | — | US | disclosed |
| US-20230028359-A1 | NUCLEOTIDE ANALOGUES | FIRST-CITIZENS BANK & TRUST COMPANY | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12215122-B2 | Nucleotide analogues | NUDT1, POLN, TYMP | EHMT2 2494/4885EHMT1 2450/4885APOBEC3G 226/4885 |
| US-20240400602-A1 | NUCLEOTIDE ANALOGUES | ADAR, NUDT1, NSUN2 | EHMT2 938/4885EHMT1 923/4885APOBEC3G 236/4885 |
| US-20240316036-A1 | DISULFIDE CONTAINING THERAPEUTICS AND DIAGNOSTICS | GPX1, GPX4, PDIA4 | EHMT2 2946/4885EHMT1 3031/4885APOBEC3G 4047/4885 |
| US-20250361260-A1 | NUCLEOTIDE ANALOGUES | ADAR, NUDT1, NSUN2 | EHMT2 938/4885EHMT1 923/4885APOBEC3G 236/4885 |
| US-20230257414-A1 | NUCLEOTIDE ANALOGUES | ITPA, POLB, NUDT1 | EHMT2 2878/4885EHMT1 3389/4885APOBEC3G 437/4885 |
| US-20240269156-A1 | DISULFIDE CONTAINING THERAPEUTICS | P4HB, PDIA5, PDIA4 | EHMT2 3151/4885EHMT1 3191/4885APOBEC3G 2768/4885 |
| US-20230028359-A1 | NUCLEOTIDE ANALOGUES | ITPA, POLB, NUDT1 | EHMT2 2878/4885EHMT1 3389/4885APOBEC3G 437/4885 |
| US-11958877-B2 | Nucleotide analogues | ITPA, POLB, NUDT1 | EHMT2 2878/4885EHMT1 3389/4885APOBEC3G 437/4885 |
| US-20230203083-A1 | NUCLEOTIDE ANALOGUES | ITPA, POLB, NUDT1 | EHMT2 2878/4885EHMT1 3389/4885APOBEC3G 437/4885 |
| US-20240174709-A1 | NUCLEOTIDE ANALOGUES | NUDT1, POLN, TYMP | EHMT2 2494/4885EHMT1 2450/4885APOBEC3G 226/4885 |
| US-11878993-B2 | Nucleotide analogues | ITPA, POLB, NUDT1 | EHMT2 2878/4885EHMT1 3389/4885APOBEC3G 437/4885 |
| US-12145960-B2 | Nucleotide analogues | ITPA, POLB, NUDT1 | EHMT2 2878/4885EHMT1 3389/4885APOBEC3G 437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.